Published in Infect Immun on February 01, 1999
Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun (2005) 1.35
Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens. Infect Immun (2005) 1.14
Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine. Infect Immun (2002) 1.08
Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun (2002) 1.03
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine (2007) 0.86
Modified heat-stable toxins (hSTa) of enterotoxigenic Escherichia coli lose toxicity but display antigenicity after being genetically fused to heat-labile toxoid LT(R192G). Toxins (Basel) (2011) 0.83
Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines. Infect Immun (2001) 0.82
Vaccinating against Helicobacter pylori in the developing world. Gut Microbes (2013) 0.80
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Nature of the skin-reactive principle in culture filtrates prepared from Paracoccidioides brasiliensis. J Bacteriol (1967) 3.82
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine (1988) 3.00
Delayed hypersensitivity in the mouse. Adv Immunol (1975) 2.95
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Antibody response that protects against disseminated candidiasis. Infect Immun (1995) 2.31
Antibody immunity and invasive fungal infections. Infect Immun (1995) 2.31
Fungal flora of the normal human small and large intestine. N Engl J Med (1969) 2.25
Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A (1996) 2.00
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis (1995) 1.97
Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun (1986) 1.86
Serological and cellular immune activity of peptidoglucomannan fractions of Candida albicans cell walls. Infect Immun (1974) 1.76
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun (1997) 1.68
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun (1991) 1.55
Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J Infect Dis (1997) 1.51
Active immunization of mice against Candida albicans. Proc Soc Exp Biol Med (1961) 1.51
Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology (1991) 1.49
Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol (1996) 1.46
Cholera toxin and its subunits as potential oral adjuvants. Curr Top Microbiol Immunol (1989) 1.43
Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine (1994) 1.32
Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Infect Immun (1978) 1.31
Experimental murine candidiasis: pathological and immune responses in T-lymphocyte-depleted mice. Infect Immun (1978) 1.31
Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol (1998) 1.29
Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine (1997) 1.26
The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci (1996) 1.26
Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans. Infect Immun (1978) 1.25
Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans. Antimicrob Agents Chemother (1987) 1.16
Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J Med Vet Mycol (1993) 1.08
Course of primary candidiasis in T cell-depleted mice infected with attenuated variant cells. J Infect Dis (1992) 1.07
In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun (1989) 1.07
A 70-kilodalton recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun (1998) 1.04
Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine (1996) 0.99
Delayed-type hypersensitivity in the mouse. I. Induction and elicitation by Salmonella adelaide flagellin and its derivatives. Scand J Immunol (1972) 0.98
Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect Immun (1993) 0.96
Immunoprotection against systemic candidiasis in mice. Int Immunol (1995) 0.95
Production of antibodies to antigens of Candida albicans in CBA/H mice. Infect Immun (1994) 0.89
Immunoblotting analysis of sera from patients with candidal vaginitis and healthy females. J Med Vet Mycol (1992) 0.87
Induction of systemic immune responses to measles virus synthetic peptides administered intranasally. Vaccine (1995) 0.83
Systemic candidiasis in mice immunized with Candida albicans ribosomes. Mycopathologia (1985) 0.82
Identification of immunodominant antigens of Candida albicans in patients with superficial candidosis. Clin Immunol Immunopathol (1990) 0.81
Active immunity in experimental candidiasis in mice. Sabouraudia (1967) 0.80
Protection against systemic infections with various Candida species elicited by vaccination with Candida albicans ribosomes. Sabouraudia (1985) 0.78
Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice. Vaccine (1997) 0.77
Effect of immunization with formalin killed cells in complete Freund's adjuvant in experimental candidosis. Indian J Med Res (1985) 0.77
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Nonuniform probability of glutamate release at a hippocampal synapse. Science (1993) 4.23
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun (1978) 3.95
Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun (1978) 3.80
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun (1981) 3.15
Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature (1990) 3.14
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 2.44
Direct measurement of specific membrane capacitance in neurons. Biophys J (2000) 2.39
Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med (1996) 2.38
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev (1992) 2.02
Growth and differentiation of human nasal epithelial cells in culture. Serum-free, hormone-supplemented medium and proteoglycan synthesis. Am Rev Respir Dis (1985) 1.87
Mucosal adjuvants. Vaccine (2005) 1.86
Monosaccharide and chitin content of cell walls of Histoplasma capsulatum and Blastomyces dermatitidis. J Bacteriol (1971) 1.81
Immune responses to Candida albicans in genetically distinct mice. Infect Immun (1982) 1.78
Comparative study of the cell walls of the yeastlike and mycelial phases of Histoplasma capsulatum. J Bacteriol (1967) 1.73
Heteromeric AMPA receptors assemble with a preferred subunit stoichiometry and spatial arrangement. Neuron (2001) 1.72
Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun (1984) 1.70
Immunological and physicochemical characterization of heat-labile enterotoxins isolated from two strains of Escherichia coli. Infect Immun (1982) 1.70
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A (1997) 1.61
Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin. Infect Immun (1996) 1.60
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol (2001) 1.59
Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine (1998) 1.58
A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. J Biol Chem (2000) 1.56
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia (2008) 1.55
Presynaptic glutamate receptors depress excitatory monosynaptic transmission between mouse hippocampal neurones. J Physiol (1990) 1.52
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood (2000) 1.52
Effects of cyclophosphamide on murine candidiasis. Infect Immun (1980) 1.50
Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J (1996) 1.49
Does surface chemistry affect thrombogenicity of surface modified polymers? J Biomed Mater Res (2001) 1.45
Septicemia caused by Capnocytophaga in a granulocytopenic patient with glossitis. Arch Intern Med (1980) 1.44
Mutation in RAP1 is a rare event in myelodysplastic syndromes. Leukemia (2005) 1.44
Development of a vaccine of cross-linked heat-stable and heat-labile enterotoxins that protects against Escherichia coli producing either enterotoxin. Infect Immun (1982) 1.44
Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun (1989) 1.43
Oral immunization of mice with attenuated Salmonella enteritidis containing a recombinant plasmid which codes for production of the B subunit of heat-labile Escherichia coli enterotoxin. Infect Immun (1986) 1.43
[Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance]. Nephrologie (2002) 1.41
Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ (1995) 1.41
Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation. Possible involvement of the ubiquitinated Cis protein. J Biol Chem (1998) 1.39
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia (2011) 1.37
Quantal amplitude and quantal variance of strontium-induced asynchronous EPSCs in rat dentate granule neurons. J Physiol (1999) 1.37
Arousal of mucosal secretory immunoglobulin A antitoxin in rats immunized with Escherichia coli heat-labile enterotoxin. Infect Immun (1982) 1.36
Endoplasmic reticulum retention is a common defect associated with tyrosinase-negative albinism. Proc Natl Acad Sci U S A (2000) 1.32
A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol Cell Biol (1998) 1.32
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia (2010) 1.32
Initiation of multi-leaf collimator conformal radiation therapy. Int J Radiat Oncol Biol Phys (1993) 1.32
Characterization of Candida albicans mannan-induced, mannan-specific delayed hypersensitivity suppressor cells. Infect Immun (1990) 1.31
Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge. Infect Immun (1978) 1.31
Experimental murine candidiasis: pathological and immune responses in T-lymphocyte-depleted mice. Infect Immun (1978) 1.31
Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol (1998) 1.29
Vaccine for enterotoxigenic Escherichia coli based on synthetic heat-stable toxin crossed-linked to the B subunit of heat-labile toxin. J Infect Dis (1983) 1.29
Effect of catecholamines on ion transport in dog tracheal epithelium. J Appl Physiol Respir Environ Exerc Physiol (1979) 1.28
The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine (1999) 1.28
Biology of erythropoietin. Haematologica (1998) 1.26
Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun (1994) 1.25
Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans. Infect Immun (1978) 1.25
In vivo induction of interleukin-12 mRNA expression after oral immunization with Salmonella dublin or the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1995) 1.24
The molecular biology of erythropoietin. Nephrol Dial Transplant (1999) 1.23
Photolytic manipulation of [Ca2+]i reveals slow kinetics of potassium channels underlying the afterhyperpolarization in hippocampal pyramidal neurons. J Neurosci (1999) 1.23
Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein. Infect Immun (1985) 1.21
Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers. Vaccine (1994) 1.20
Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol (1999) 1.18
Nonuniform distribution of Ca2+ channel subtypes on presynaptic terminals of excitatory synapses in hippocampal cultures. J Neurosci (1997) 1.18
In vivo and in virto cellular responses to cytoplasmic and cell wall antigens of Histoplasma capsulatum in artificially immunized or infected guinea pigs. Infect Immun (1976) 1.17
Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine (1993) 1.17
Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors. Vaccine (1993) 1.17
Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine. Infect Immun (1983) 1.17
Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans. Antimicrob Agents Chemother (1987) 1.16
Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Infect Immun (1991) 1.15
Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol (1999) 1.15
N- and P/Q-type Ca2+ channels mediate transmitter release with a similar cooperativity at rat hippocampal autapses. J Neurosci (1998) 1.15
Protection in rats immunized with Escherichia coli heat-stable enterotoxin. Infect Immun (1981) 1.13
Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol (2000) 1.13
Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol (1999) 1.13
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids. Infect Immun (2001) 1.12
Multimeric structure of the membrane erythropoietin receptor of murine erythroleukemia cells (Friend cells). Cross-linking of erythropoietin with the spleen focus-forming virus envelope protein. J Biol Chem (1991) 1.12
Immunization of rats with heat-labile enterotoxin provides uniform protection against heterologous serotypes of enterotoxigenic Escherichia coli. Infect Immun (1981) 1.11
Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood (1999) 1.11
Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin-responsive cells. J Biol Chem (1992) 1.11
Mammary gland contamination as a means of establishing long-term gastrointestinal colonization of infant mice with Candida albicans. Infect Immun (1982) 1.09
Postsynaptic expression of long-term potentiation in the rat dentate gyrus demonstrated by variance-mean analysis. J Physiol (1999) 1.09
In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun (1999) 1.08
In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun (1989) 1.07
Cloning and molecular characterization of the B subunit of Escherichia coli heat-labile enterotoxin. Infect Immun (1983) 1.06
Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp. Infect Immun (1996) 1.05
Translation rate of human tyrosinase determines its N-linked glycosylation level. J Biol Chem (2000) 1.05
Innate and acquired immune responses against Candida albicans in congenic B10.D2 mice with deficiency of the C5 complement component. J Med Vet Mycol (1986) 1.04
Cell wall studies of Histoplasma capsulatum and Blastomyces dermatitidis using autologous and heterologous enzymes. Infect Immun (1977) 1.03
Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol (2000) 1.03
Intracellular Salmonella dublin induces substantial secretion of the 40-kilodalton subunit of interleukin-12 (IL-12) but minimal secretion of IL-12 as a 70-kilodalton protein in murine macrophages. Infect Immun (1997) 1.02
Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol (2012) 1.02